- Home
- DTIL vs CGTX Comparison
DTIL vs CGTX Comparison
Compare DTIL & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTIL | CGTX |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 94.5M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DTIL | CGTX |
|---|---|---|
| Price | $5.35 | $1.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $60.00 | $3.33 |
| AVG Volume (30 Days) | 158.4K | ★ 637.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 106.52 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,070,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $34.30 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.53 | $0.22 |
| 52 Week High | $8.82 | $3.83 |
Technical Indicators
Market Signals| Indicator | DTIL | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 73.35 | 52.72 |
| Support Level | $5.29 | $1.00 |
| Resistance Level | $5.67 | $1.19 |
| Average True Range (ATR) | 0.29 | 0.07 |
| MACD | 0.13 | 0.02 |
| Stochastic Oscillator | 97.65 | 86.11 |
Price Performance
Historical ComparisonAbout DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.